With no "cure," neovascular age-related macular degeneration remains a key disease state for numerous pharmaceutical companies. Here is a brief overview with the status of clinical trials and investigations.
Ongoing treatment with anti-VEGF injections or photodynamic therapy is, to date, the primary means of managing and treating AMD. Here is a look at some of the patient-access programs specific to retinal disorders/AMD.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
